Outpatient Oncology Infusion Market Analysis

Outpatient Oncology Infusion Market Analysis

To get key market trends

  Download Free Sample

Based on product, the market is classified into infusion pumps

intravenous sets, IV cannulas, and needleless connectors. The infusion pumps segment generated the highest revenue of USD 1.2 billion in 2023.
 

• The adoption of IV infusion pumps for cancer therapies at outpatient facilities is increasing due to their precision in drug delivery, ability to administer complex chemotherapy regimens, and improved patient outcomes. Further, infusion pumps provide continuous and controlled delivery of chemotherapeutic agents, reducing dosage errors and enhancing treatment efficacy.
   
• Additionally, advancements in pump technology, including programmable and smart pumps, have enhanced their reliability and ease of use, which is expected to further drive segment growth during the forecast period. For instance, in April 2024, Baxter International Inc. received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Novum IQ large volume infusion pump (LVP) with Dose IQ Safety Software, an advanced infusion pump featuring intelligent programming capabilities.
   

Based on application, the outpatient oncology infusion market is classified into lung cancer, liver cancer, breast cancer, prostate cancer, and other cancers. The breast cancer segment dominated the market in 2023 with a market share of 20.5%.
 

• The growth of this segment can be attributed to high prevalence of breast cancer worldwide, diverse and advanced treatment options, patient preference for outpatient care, supportive care services, and patient education and support programs. For instance, as per Global Cancer Statistics 2022, 2.3 million new cases were diagnosed with female breast cancer in 2022.
   
• Additionally, the widespread and effective breast cancer screening programs lead to early detection. Early-stage breast cancer diagnosis often requires infusion-based treatments such as chemotherapy, targeted therapy, and hormone therapy, which are well-suited for administration in outpatient settings.
   

Based on therapy, the outpatient oncology infusion market is segmented into chemotherapy, targeted therapy, immunotherapy, and hormonal therapy. The targeted therapy segment dominated the market in 2023 and is anticipated to reach USD 1.5 billion by 2032.
 

• Targeted therapies, such as monoclonal antibodies and small molecule inhibitors, offer personalized treatment options based on the genetic makeup of a patient's tumor. This precision leads to improved efficacy and fewer side effects compared to traditional chemotherapy.
   
• Moreover, advances in molecular diagnostics have facilitated the identification of specific targets, enhancing the development and application of these therapies. The convenience of outpatient settings allows for easier administration and monitoring, further driving their popularity. Consequently, targeted therapies are transforming cancer treatment paradigms, contributing to better patient outcomes and higher adoption rates in outpatient oncology infusion.
   

Based on mode, the outpatient oncology infusion market is segmented into intramuscular (IM), intravenous (IV), subcutaneous, and other modes. The intravenous (IV) segment dominated the market in 2023 and is anticipated to reach USD 1.3 billion by 2032.
 

• IV administration allows for the direct delivery of chemotherapy and other therapeutic agents into the bloodstream, ensuring rapid and controlled absorption. Further, there is substantial rise in healthcare facilities that are providing IV therapies for cancer, which is further expected to accelerate segment growth. For instance, in July 2023, MidLantic Urology introduced IV immunotherapy infusion service for people suffering from bladder cancer.  
   
• The rise in targeted therapies, which often require IV administration, also contributes to the growing adoption of IV modes. These therapies are tailored to individual patients' genetic profiles, offering more effective and personalized treatment options.
   

North America outpatient oncology infusion market accounted for USD 1 billion market revenue in 2023 and is anticipated to grow at a CAGR of 10% between 2024 – 2032 period.
 

• The region's dominance can be attributed to several factors, including the rising prevalence of cancer, which is driving the demand for accessible and efficient treatment options, such as outpatient oncology infusion settings.
   
• North America benefits from a high level of cancer awareness and the importance of early diagnosis. Public health campaigns, screening programs, and advances in diagnostic technologies have contributed to earlier cancer detection, enabling timely intervention and treatment.
   

U.S. outpatient oncology infusion market is accounted for USD 949.2 million market revenue in 2023 and is anticipated to grow at a CAGR of 9.8% during the forecast period.
 

• The growth of the U.S. market is attributed to favorable healthcare policy, technological advancements, and patient preference. The Affordable Care Act and other healthcare reforms have expanded access to cancer treatment, encouraging the use of outpatient services to reduce overall healthcare costs.
   
• In addition, the high cost of inpatient care drives both providers and patients to seek more cost-effective solutions, with outpatient oncology infusion being a key component. Insurance companies in the U.S. also play a significant role by offering coverage for outpatient treatments, further promoting their adoption.
   

Germany outpatient oncology infusion market is projected to grow remarkably in the coming years.
 

• In Germany, the growing adoption of outpatient oncology infusion is driven by the country’s robust healthcare infrastructure and a strong focus on efficient resource utilization. The German healthcare system prioritizes high-quality care and cost-effectiveness, leading to a preference for outpatient settings where feasible. The establishment of specialized outpatient oncology centers equipped with advanced infusion technologies has further supported this transition.
   
• Additionally, the aging population and increasing cancer incidence in the country create a need for scalable and accessible treatment options, which outpatient infusion centers are well-positioned to provide.
   

Japan holds a dominant position in the Asia Pacific outpatient oncology infusion market.
 

• In Japan, the adoption of outpatient oncology infusion is driven by the country's demographic trends and consolidated healthcare infrastructure coupled with healthcare policies. Japan has one of the highest aging populations in the world, leading to a significant increase in cancer cases. Outpatient oncology infusion centers offer a practical solution to meet the growing demand for cancer treatment while managing healthcare costs.
   
• The Japanese healthcare system emphasizes accessibility and efficiency, with a strong network of outpatient clinics that provide comprehensive cancer care. Technological advancements in infusion therapies and the availability of targeted treatments that can be safely administered in outpatient settings contribute to this trend.